Repare Therapeutics Inc.
RPTX
$1.43
$0.010.70%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.07M | 53.48M | 66.52M | 68.68M | 97.86M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.07M | 53.48M | 66.52M | 68.68M | 97.86M |
| Cost of Revenue | 678.00K | 13.38M | 6.36M | 10.67M | 14.38M |
| Gross Profit | 395.00K | 40.10M | 60.17M | 58.02M | 83.48M |
| SG&A Expenses | 31.25M | 32.22M | 34.42M | 35.84M | 36.24M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 131.96M | 145.62M | 158.74M | 164.47M | 168.59M |
| Operating Income | -130.88M | -92.14M | -92.22M | -95.79M | -70.73M |
| Income Before Tax | -126.71M | -83.25M | -82.42M | -83.68M | -58.06M |
| Income Tax Expenses | 1.18M | 1.44M | 1.63M | -15.15M | -12.37M |
| Earnings from Continuing Operations | -127.89 | -84.69 | -84.05 | -68.52 | -45.69 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -127.89M | -84.69M | -84.05M | -68.52M | -45.69M |
| EBIT | -130.88M | -92.14M | -92.22M | -95.79M | -70.73M |
| EBITDA | -128.28M | -90.22M | -90.24M | -93.80M | -68.72M |
| EPS Basic | -3.01 | -1.99 | -1.98 | -1.62 | -1.09 |
| Normalized Basic EPS | -1.80 | -1.20 | -1.19 | -1.24 | -0.86 |
| EPS Diluted | -3.01 | -2.00 | -2.00 | -1.63 | -1.10 |
| Normalized Diluted EPS | -1.80 | -1.21 | -1.20 | -1.25 | -0.87 |
| Average Basic Shares Outstanding | 170.00M | 169.64M | 169.27M | 168.92M | 168.57M |
| Average Diluted Shares Outstanding | 170.00M | 171.43M | 171.06M | 170.71M | 170.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |